# Psychiatry Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Abraham Lincoln (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI001-SYN-TD
- Date: 1841-08-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Priya Natarajan, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Elena Marquez, MD

## Reason for consultation

Moderate major depressive disorder, single episode, in a 32-year-old attorney starting sertraline 50 mg daily. Please confirm the diagnosis, look for bipolar spectrum illness, review his suicide risk and safety plan, and advise on medication management and psychotherapy. **S**

## History

Mr. Lincoln is seen at the request of Dr. Marquez six weeks after starting sertraline 50 mg daily for a depressive episode with low mood, loss of interest, poor sleep, and poor concentration. His mood is brighter on most days, he is back at court on his usual schedule, and he writes to friends again. He falls asleep within half an hour and wakes once a night. Mild nausea settled by the third week; he has had no restlessness, agitation, or sexual side effects, and he misses about one dose every two weeks. He describes no past periods of elevated or irritable mood, reduced need for sleep, racing thoughts, or unusual risk-taking, and no hallucinations or unusual beliefs. He uses no alcohol, tobacco, or other drugs. He has had no suicidal thoughts since the intake visit and carries his safety plan. No prior suicidal behavior is recorded. He lost his mother at nine and his older sister in his late teens, and he spoke about those losses without current preoccupation. He prefers to continue medication alone for now. **S**

## Examination

| System | Finding |
|---|---|
| Appearance and behavior | Tall, neatly dressed, good eye contact, cooperative and engaged |
| Speech | Normal rate and volume; articulate, with dry humor |
| Mood and affect | Mood "better, not yet myself"; affect mildly constricted but brighter and reactive |
| Thought process | Linear and goal-directed |
| Thought content | No suicidal or homicidal ideation, intent, or plan; no delusions |
| Perception | No hallucinations |
| Cognition | Alert and oriented; attention and memory intact in conversation |
| Insight and judgment | Good |

BP 116/72 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.8 °C; oxygen saturation 99% on room air; weight 82.4 kg; BMI 22.1 kg/m². All vital signs are synthetic.

## Data reviewed

PHQ-9 14 at intake and 9 today; the intake safety assessment and collaborative safety plan; today's vital signs; the medication list. No laboratory tests are on record, and none are needed for sertraline. Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]: 9. All results are synthetic.

## Assessment

1. **Major depressive disorder, single episode, moderate** (F32.1). Diagnosis confirmed. The episode is uncomplicated: no psychotic features, no substance use, and no earlier episode on record. The PHQ-9 has fallen from 14 to 9 in six weeks, a 36 percent reduction: a partial response that is still improving on a well-tolerated starting dose. **S**
2. **Bipolar spectrum illness**. Not suspected. There is no history of hypomanic or manic symptoms and no activation on sertraline. No Mood Disorder Questionnaire was done at intake; after this interview it adds little now. **S**
3. **Suicide risk**. Acute risk is low: no ideation, intent, plan, or preparatory behavior; access to lethal means has been reviewed; he is engaged in care and has strong protective factors in his friendships and his sense of purpose. The active depressive episode keeps risk above his baseline until remission. The collaborative safety plan is appropriate, and outpatient care is the right setting. **S**

## Recommendations

1. Continue sertraline 50 mg daily; he is improving steadily and tolerating it well.
2. Increase to 100 mg if the PHQ-9 is not below 5 at the twelve-week review.
3. PHQ-9 at least monthly until remission, so a nurse telephone check in about four weeks, then every two to four weeks in the continuation phase.
4. Reassess suicide risk at every visit with the C-SSRS Since Last Visit or PHQ-9 item 9, and keep the safety plan current; 988 at any time.
5. After remission, continue sertraline at the dose that achieved it for at least six months, then taper gradually with his clinician rather than stopping suddenly.
6. Psychotherapy (cognitive behavioral or interpersonal therapy) is a reasonable addition but not required for an uncomplicated episode. He prefers medication alone, and the guideline supports monotherapy; offer it again if his response stalls or he relapses.
7. No laboratory monitoring is needed for sertraline. Avoid regular NSAIDs and other serotonergic drugs such as tramadol, triptans, St John's wort, and dextromethorphan without checking first.
8. Reassess for bipolar disorder, using the Mood Disorder Questionnaire, if elevated mood, reduced need for sleep, or racing thoughts appear.

## Strengths and supports

- Supports: close friend and law colleagues; values correspondence and storytelling **S**

## Communication

Discussed with Dr. Marquez in person today; the patient agrees with the plan. **S**

## Follow-up

Primary care will continue measurement-based care on the CMID schedule. Psychiatry will see him again if the PHQ-9 has not halved after a dose increase, for any suicidal ideation, or for features of bipolar disorder. **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
